GB2356346A - Food product for oral delivery of a pharmaceutical agent to a non-human animal comprising encapsulated particles of said agent distributed within the product - Google Patents
Food product for oral delivery of a pharmaceutical agent to a non-human animal comprising encapsulated particles of said agent distributed within the product Download PDFInfo
- Publication number
- GB2356346A GB2356346A GB9927474A GB9927474A GB2356346A GB 2356346 A GB2356346 A GB 2356346A GB 9927474 A GB9927474 A GB 9927474A GB 9927474 A GB9927474 A GB 9927474A GB 2356346 A GB2356346 A GB 2356346A
- Authority
- GB
- United Kingdom
- Prior art keywords
- food product
- agent
- food
- product according
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 84
- 239000002245 particle Substances 0.000 title claims abstract description 53
- 239000008177 pharmaceutical agent Substances 0.000 title claims abstract description 47
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 32
- 241001465754 Metazoa Species 0.000 claims abstract description 42
- 239000011159 matrix material Substances 0.000 claims abstract description 32
- 238000000576 coating method Methods 0.000 claims abstract description 21
- 239000011248 coating agent Substances 0.000 claims abstract description 20
- 229920000159 gelatin Polymers 0.000 claims abstract description 9
- 235000019322 gelatine Nutrition 0.000 claims abstract description 9
- 239000003826 tablet Substances 0.000 claims abstract description 7
- 239000007937 lozenge Substances 0.000 claims abstract description 6
- 229960005486 vaccine Drugs 0.000 claims abstract description 6
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 4
- 206010006326 Breath odour Diseases 0.000 claims abstract description 3
- 229940125687 antiparasitic agent Drugs 0.000 claims abstract 3
- 239000003096 antiparasitic agent Substances 0.000 claims abstract 3
- 230000037396 body weight Effects 0.000 claims abstract 3
- 229920000591 gum Polymers 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000001828 Gelatine Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 5
- 206010003246 arthritis Diseases 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 206010016766 flatulence Diseases 0.000 claims description 2
- 235000013372 meat Nutrition 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 claims 2
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 239000004468 fish derivative Substances 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 32
- 239000007787 solid Substances 0.000 abstract description 4
- 108010010803 Gelatin Proteins 0.000 abstract 1
- 229940124346 antiarthritic agent Drugs 0.000 abstract 1
- 239000003435 antirheumatic agent Substances 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- 239000000047 product Substances 0.000 description 24
- 229960005473 fenbendazole Drugs 0.000 description 17
- IRHZVMHXVHSMKB-UHFFFAOYSA-N fenbendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 IRHZVMHXVHSMKB-UHFFFAOYSA-N 0.000 description 17
- 239000000243 solution Substances 0.000 description 13
- 239000000725 suspension Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000013459 approach Methods 0.000 description 8
- 229920000615 alginic acid Polymers 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 6
- 229940072056 alginate Drugs 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229960002957 praziquantel Drugs 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 235000019629 palatability Nutrition 0.000 description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000008393 encapsulating agent Substances 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000010410 calcium alginate Nutrition 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- 229960002681 calcium alginate Drugs 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- 239000011247 coating layer Substances 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 235000013622 meat product Nutrition 0.000 description 2
- BUTPBERGMJVRBM-UHFFFAOYSA-N methanol;methylsulfinylmethane Chemical compound OC.CS(C)=O BUTPBERGMJVRBM-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- MDNWOSOZYLHTCG-UHFFFAOYSA-N Dichlorophen Chemical compound OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O MDNWOSOZYLHTCG-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- HMCCXLBXIJMERM-UHFFFAOYSA-N Febantel Chemical compound C1=C(NC(NC(=O)OC)=NC(=O)OC)C(NC(=O)COC)=CC(SC=2C=CC=CC=2)=C1 HMCCXLBXIJMERM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003887 dichlorophen Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 235000015177 dried meat Nutrition 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960005282 febantel Drugs 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229960003439 mebendazole Drugs 0.000 description 1
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- -1 nitroscannate Chemical compound 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- VRYKTHBAWRESFI-VOTSOKGWSA-N oxantel Chemical compound CN1CCCN=C1\C=C\C1=CC=CC(O)=C1 VRYKTHBAWRESFI-VOTSOKGWSA-N 0.000 description 1
- 229960000535 oxantel Drugs 0.000 description 1
- 229960004454 oxfendazole Drugs 0.000 description 1
- BEZZFPOZAYTVHN-UHFFFAOYSA-N oxfendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1S(=O)C1=CC=CC=C1 BEZZFPOZAYTVHN-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960005134 pyrantel Drugs 0.000 description 1
- YSAUAVHXTIETRK-AATRIKPKSA-N pyrantel Chemical compound CN1CCCN=C1\C=C\C1=CC=CS1 YSAUAVHXTIETRK-AATRIKPKSA-N 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Fodder In General (AREA)
- Medicinal Preparation (AREA)
Abstract
A food product suitable for the delivery of a pharmaceutical agent to a non-human animal comprises particles of the pharmaceutical agent which are encapsulated in an inert coating and dispersed substantially uniformly throughout the palatable food matrix. The pharmaceutical agent may be any one of a wide variety of agents suitable for the treatment of illness in animals, for example, an anti-parasitic agent, a component of a vaccine, an anti-arthritic agent or an agent for treatment of unpleasant breath odour. The preferred encapsulating material is ethyl cellulose, gelatin or gum arabica and the preferred encapsulated particle size is between 1 nm and 1 mm in diameter. The food product may be moulded in solid form, <I>e.g</I>., as a tablet, lozenge, strip or chew. Each food product may correspond to the recommended unit dose of the pharmaceutical agent per unit of animal body weight and may also be divided into defined segments so that portions of the unit dose may also be administered. A number of food product may be packaged together.
Description
2356346 FOOD PRODUCT The present invention relates to food products that
contain a pharmaceutical agent dispersed within a palatable food matrix. The products are designed so that the unpleasant taste of the pharmaceutical agent is disguised. Additionally, the pharmaceutical agent is not susceptible to modification or degradation as a result of contacting compounds contained within the food matrix. This guarantees the safety of the product.
The maintenance of good health and the treatment of ill health in animals, especially companion animals, is frequently achieved by the oral administration of medications and supplements. Examples include the treatment or prevention of worms and fleas, the treatment of a range of infections and the treatment of arthritic symptoms and other ailments typical of older animals.
Typically, one or more pharmaceutical agents are dispersed within a matrix of substantially inert materials and formed into a tablet or lozenge. Inert materials are used to prevent reaction of the pharmaceutical agent with compounds contained within the food.
These inert materials are generally selected from a range of such materials that are specified in approved Pharmaceutical monographs, such as the European Pharmacopoeia. Such collections of monographs tend to exclude many of the materials which are most palatable to many animals, such as meat products and complex proteins, at least partly because their complexity makes it almost impossible to define a very precise specification for such materials. This makes it difficult to design medicinal food products that are palatable to the animal.
Palatability is of great significance, particularly for fastidious companion animals such as cats, since oral administration of an unpalatable tablet can be very difficult and on occasions even impossible, particularly when the agents to be administered are especially unpalatable to the animal.
Palatability is also important when baiting wild animals, for example, for the delivery of vaccines or other pharmaceutical formulations. In this instance, it is of the utmost importance to ensure that the active agents are successfully ingested by the wild animal, since it will be desirable for as many animals as possible to receive the intended treatment.
2 The problem of the oral administration of unpalatable medicine to animals has been recognised in the art, and a number of solutions have been proposed.
One approach is to create a product, using phannaceutical agents that are relatively stable chemically, that consists of one or more pharmaceutical agents dispersed within a palatable matrix of pet food materials. Analytical methods are then employed to validate that, within the resolution of such methods, the pharmaceutical agents are not degraded, either during processing, or simply through being in contact with food materials. Such a product, known as "Esy-Dose", is currently sold in Australia.
However, this approach has some drawbacks. Firstly, the approach will not be successful with pharmaceutical agents that are not stable in the presence of food materials. Secondly, even though analytical methods may show, within their resolution, that no degradation of the pharmaceutical agent nor any interaction of the agent with the food matrix has occurred, there is always a concern that such degradation or interaction of the pharmaceutical may in fact have occurred, but to an extent too slight to be resolved by the analytical methods available.
A related concern is that the complexity and variability of materials such as meat products, that could well be present in such a palatable matrix, may be such that the occasional batch of such a material might be exceptionally more chemically reactive towards the pharmaceutical agent. Because this event is only very occasional, this possibility may not be apparent during the validation procedures.
Such concerns have led the pharmaceutical regulatory authorities in some countries to err on the side of caution, and to indicate an unwillingness to grant licenses to companies to sell products of this type.
EP 0 574 301 (Sogeval SA) teaches an alternative solution, namely that of using a matrix of palatable food material which contains a "recess" within which a pill can be placed. A similar principle is described in International patent application W095/20942 (Atali & Vuagnoux). Experience shows, however, that many animals are quite capable of "sifting out" the less palatable pill from the more palatable matrix, thus leaving the medication substantially untouched.
3 Another approach is to disperse the pharmaceutical active within a core and to apply an outer coating layer, which includes palatable substances, as is described in US 5,683,722 (Derrieu et al.). However, experience again shows that many animals are capable of consuming palatable coatings (for example, by licking), leaving the less palatable core 5 untouched.
A variation on this theme is to affix particles of a pharinaceutical agent to a core particle of food material, as described in US 5,624,710 (Dox-AL Italia SpA). This solution is intended to facilitate subsequent distribution within a feed. However, this approach suffers from the drawback that there is no barrier between the pharmaceutical agent and the food, with the negative consequences outlined above.
Yet another approach is to disperse the active in an inert matrix of materials taken from a relatively restricted range of those which have pharmacopoeia. monographs and to create a granule, which may then be added to a feed. Such an approach is taught in US 4,597,969 (Merck, Sharp & Dohme), where the granule is formed from alginates and magnesium hydroxide. However, the ability of many animals to "sift out" particles of unpalatable material from others which are more palatable presents a significant drawback to this approach.
There thus remains a great need for a system to deliver reliably a pharmaceutical agent to an animal. Such a system would allow incorporation of the agent into food products without compromising the palatability of the food, whilst ensuring that no unwanted chemical reactions take place between the food ingredients and the pharmaceutical.
Summga of the invention According to the invention, there is provided a food product for the oral delivery of a pharmaceutical agent to a non-human animal, comprising particles of said agent dispersed substantially uniformly within a palatable food matrix, wherein each of said particles is encapsulated within a substantially inert coating.
The food products of the invention have the advantage that they greatly increase the ease and chance of success of oral administration, by suppressing the unpalatable taste of the medicament, whilst minimising the risks associated with bringing pharmaceutical agents directly into contact with food components. The pharmaceutical agent is isolated from the 4 food material by virtue of the inert coating surrounding the agent, meaning that no undesirable reactions can occur between the pharmaceutical agent and the other ingredients of the food product. This greatly increases the range of pharmaceutical agents that may be included in food products. Furthermore, a large selection of food ingredients may be used to ensure that the product exhibits the desired degree of palatability to the target animal, since the selection is not limited to the substantially inert materials that are generally approved for contact with pharmaceutical agents.
A ftirther advantage of the food products of the invention is that they provide an excellent mechanism by which to control the dosage of medicament that is applied to the animal. A certain product type, designed for a particular application to a specific target animal, will therefore contain a controlled amount of medicament. This amount should correspond to the desired dosage for a particular unit weight of animal, for example, a 10kg unit weight. The owner or carer of the animal can in this way administer the required dosage simply by reference to the weight of the animal. In this example, a 30kg animal would be given three food products.
The food products of the invention may be liquid, semi-solid or solid in form. Solid food products may be formed into lozenges or tablets that contain a particular unit dose of pharmaceutical agent. Strips or chews may also be used. Semi-solid products may take the form of a porridge or broth. Liquid food products may be packaged into cans or tins, preferably in amounts corresponding to a particular unit dose.
The food matrix may be any material that is palatable, non-toxic, and easily ingestable, including solid, semi-solid and liquid materials. Preferably, the matrix is easily digestible by the animal. Suitable food materials may be selected from those used conventionally in pet foods and livestock feed, as the skilled reader will appreciate. Typically, the matrix will contain flours and starches and other materials necessary to aid processing, impart colour, act as preservatives, impart texture and so on.
A selection of typical ingredients is given below, with the function of each ingredient given in parentheses: poultry meal (protein source, palitant); soya bean oil (fat, aid to processing); poultry liver powder (protein, palitant); sugar (flavour, humectant); glycerol (softener, humectant); water (texture former, aid to processing); maltose glucose syrup (flavour, humectant); salt (flavour, humectant); dark malt flour (starch, colorant); red iron oxide (mineral); burnt sugar (flavour); pre-gel waxy maize starch (starch, texture former); turkey flavour (flavour, palitant); roche D20 (antioxidant).
For administration to carnivorous companion animals such as dogs and cats, meat and fishbased materials may also be used in the food matrix. These materials are generally derived from dried meat and fish products that are then formed into powders for incorporation into food materials.
Milk is particularly suitable as a food matrix for a liquid food product, since it is highly palatable, allows homogenous dispersion of the encapsulated particles of pharmaceutical agent and may be easily packaged and stored without risk of degradation.
The products may optionally be divided into fractions to allow precise administration of the correct dose to an animal that falls between two weight groupings. For example, a product in the form of a lozenge, tablet, strip or chew may be marked into segments (for example, into quarters).
The products of the invention may be administered directly to the animal, for example, by 15 hand. Alternatively, the products may be mixed into the animal's food. For ease of ingestion, solid food products such as lozenges or tablets may be broken into small portions, once the correct number of units has been measured out.
A large range of pharinaceutical agents may be included in the food products of the invention, as will be clear to the skilled reader. After an animal has been formally diagnosed by a veterinary surgeon as suffering from a particular disease or condition, a course of medicaments may be prescribed. Particular examples include agents to treat or prevent parasite infestation, such as anti-worming agents, agents directed against stiffness or arthritis, components of vaccines, anti-flatulence agents, antibiotics, agents for the treatment of obesity, agents for the treatment of motor disorders, agents for the treatment of senility, agents for the treatment of elevated blood pressure, anti- inflammatory agents, oral rehydration agents, hormones, diuretics, cardiovascular and respiratory preparations, products to thin the blood or enhance circulation and agents directed against unpleasant breath odour. Other examples will be quite clear to the skilled reader and many are listed in appropriate reference works such as the National Office of Animal Health compendium of data sheets for veterinary products.
6 For many conditions, such as, for example, worm infections the carer or owner of the animal may be able to diagnose a suitable treatment without needing to consult a vet. The food products of the invention may thus be available over the counter in stores such as supermarkets and pet shops.
For application to companion animals such as dogs, cats, rabbits and the like, particularly suitable examples of pharmaceutical agents include anti-worming compounds such as dichlorophen, febantel, fenbendazole, mebendazole, nitroscannate, piperazine, praziquantel, pyrantel, and oxantel. Medicament may also be applied to livestock, such as horses, cattle, sheep, pigs and goats. Examples of suitable agents include albendazole and oxfendazole.
Of course, in cases where the pharmaceutical agents are compatible with one other, the agents may be combined into one product type to give a combined medicament. In cases where pharmaceutical agents would react undesirably with one another if brought into contact, each agent may be individually encapsulated and mixed into the food matrix separately. In a further embodiment, individually encapsulated pharmaceutical agents may be agglomerated into combined particles and further encapsulated.
It is also intended that wild animals susceptible to disease may be treated using bait laced with the food products of the invention. In this manner, a vaccine such as, for example, an anti-rabies vaccine, may be administered to wild animals such as foxes. Animals such as deer may be treated with anti-tick vaccines. Other examples will be apparent to those of skill in the art and will vary throughout the countries of the world. In certain circumstances, poisons may also be delivered using the food products of the invention, for example, to limit a pest population.
The pharmaceutical agent should be dispersed throughout the food matrix as small encapsulated particles. The size of these particles may vary between certain limits, depending on various factors such as the nature of the medicament, the method of processing, the target animal species, the cost of production and the intended sales value of the food products. The particle size should be small enough that the integrity of the encapsulated pharmaceutical is retained through the manufacturing process; if the particles are too large, there is a risk that during mixing of the particles within the food matrix, the particles will become broken by shearing forces. Furthermore, a large particle size 7 increases the chance that the particles may become broken during chewing of the food by the animal, meaning that the unpalatable pharmaceutical agent will be tasted and the food rejected.
However, there is no need to generate very minute particles and indeed, the expense 5 involved in the production of extremely small particles is significant. Generally, the particles will be between 100nm and Inim in diameter, preferably between I and 500tm diameter, more preferably between 150 and 500tm diameter.
The thickness of the encapsulating coating may also be varied, depending on the particular requirements of each system. The coating must be sufficiently mechanically robust to withstand the high shearing forces encountered during the production and molding process, but must not be so thick that the particles pass through the digestive system without being ingested. An additional factor is that as more coating material is used in the production process, the cost of materials increases. Ideally, the coating should be thick enough to prevent it degrading until the food has passed out of the buccal cavity into the lower regions of the oesophagus, where the palatability of the food is no longer of concern. A preferred range for the thickness of the coating is between Iran and 100tm, more preferably, between 20nm and 100run. The ratios of coating to core may vary between around 1:20, to around 1:1, depending upon the particular requirements and properties desired of the food product.
The use of encapsulation is very widespread, particularly in the pharmaceutical industry (see, for example, Saeki and Hosoi (1984) Biochemistry and Biotechnology 10:251; Tirkkonen et al., (1994) J. Microencapsulation 11 (6), 615-626; Takeda et al., (1981) 29(l), 264; Palmieri et al., (1992) Drug development and industrial pharmacy 22(9& 10), 951; Meyer (1992), Chimia 46, 101; Koida et al., (1983) Chem. Pharm. Bull. 331(12), 4476; Jalsenjak et al., (1976) J. Pharm. Pharmac., 28, 912; Tirkkonen and Paronen (1993) Int. J.
Pharmaceutics 92: 55; Al-Musa et al., (1999) 57: 223). Often, the purpose is to control the release of a pharmaceutical agent after administration, so that, for example, it is released in a particular part of the digestive system or it is released gradually over time so that the duration of its effect is extended. Encapsulation has also been used in both pharmaceuticals and flavour compounds to help to protect from losses during processing.
8 The encapsulating coating should be made or derived from substantially inert materials specified by a monograph in a recognised pharmacopoeia, such as the European Pharmacopoeia. Other suitable encapsulating agents will be known to those of skill in the art. Examples of inert encapsulating materials include ethyleellulose, gelatine and gum arabic. By "substantially inert" is meant that the material is non- reactive chemically under conditions of normal temperature and pressure with food matrix materials and with pharmaceutical agents. The encapsulating coating should not itself be a recognised pharmaceutical agent and should be safe to eat.
Any method of generation and encapsulation of small particles will be suitable for use in the present invention, as the skilled reader will appreciate. In general, there are three main methods by which encapsulated particles may be most easily generated.
For pharmaceutical agents that are soluble in organic solvents, and that are insoluble in water, a co-assivation technique may be applied. A particulate suspension of the agent is prepared, for example, in a solution of ethylcellulose in cyclohexane. This solution is then stirred vigorously. The particles will in this manner gradually become encased within an ethylcellulose coating. The size of the particles can be controlled by the speed of stirring the solution; faster stirring will result in a smaller particle size. The thickness of the coating may be controlled by altering the amount of encapsulating agent that is present in the solvent. A larger amount of encapsulating agent will increase the thickness of the coating layer.
A second method, also suitable for use witl water-insoluble pharmaceutical agents, involves spraying a solution of the pharmaceutical agent into a bath of calcium chloride. The pharmaceutical agent may be dissolved in a sodium alginate solution and then sprayed into the bath, thus creating an atomised aerosol that forms encapsulated particles. The force with which the liquid is sprayed controls the particle size; the faster spraying is operated, the smaller will be the resulting particle size. Again, the thickness of the coating can be controlled by varying the content of encapsulating material.
A third method utilises co-assivation of a gelatine/guin arabic mixture in an aqueous solution, within which the pharmaceutical agent is dispersed. The suspension is stirred until the particles reach the desired size, then the pH is adjusted, forcing the gelatine/gum arabic mixture back out of solution to form deposits on the surface of each particle. The 9 thickness of the encapsulated layer can be controlled by varying the content of the gelatine/gum arabic material.
Once the particles of encapsulated pharmaceutical have been prepared, they are mixed into the food matrix to form a homogenous mixture, in which the particles are mixed substantially uniformly. By "substantially uniformly" is meant that the particles are dispersed throughout the food matrix and do not agglomerate together in lumps. To ensure that a substantially uniform dispersion is created, the food matrix must be mixed with the particles for a sufficient time. As the skilled reader will appreciate, the mixing period will differ for different particle sizes and for different food matrix materials. If necessary, samples can be taken at time points during the mixing process and analysed to assess the degree to which mixing has occurred. The most effective way to ensure that complete mixing has occurred is to blend the mixture for an extended period of time.
In the case of solid products, the mixture of food matrix and encapsulated pharmaceutical particles that results at the end of the mixing process may then be molded into the desired shape. These products may be any shape, but will normally be spherical, square, rectangular, cylindrical or pill-shaped. However, to increase their consumer appeal, the products may be formed into attractive shapes such as, for example, the shape of a bone. As discussed above, molded products may include indentations that mark out fractions of the product, so allowing the product to be broken into segments to facilitate the correct dosing. Finally, the products will be packaged for sale. Packages that contain one or more food products as described above are included as part of the present invention.
According to a further aspect of the invention, there is provided a process for the production of a food product containing a pharmaceutical agent suitable for administration to a non-human animal, comprising the step of dispersing particles of said agent substantially uniformly within a palatable food matrix, wherein each of said particles is encapsulated within a substantially inert coating.
According to a still further aspect of the invention, there is provided a food product according to any one of the above-described aspects of the invention, for use in therapy of a non-human animal. The invention also provides the use of particles of a pharmaceutical agent encapsulated within a substantially inert coating and dispersed within a palatable food matrix, in the manufacture of a medicament for the treatment or prevention of a disease in a non-human animal.
A still further aspect of the invention provides a method of treating a disease, or of preventing incidence of a disease in a non-human animal, comprising administering to said animal, a food product according to any one of the aspects of the invention described above.
Various aspects and embodiments of the invention will now be described in more detail by way of example, with particular reference to fenbendazole and praziquantel as pharmaceutical agents. It will be appreciated that modification of detail may be made without departing from 10 the scope of the invention.
Examples
Example I: Encgpsulation of Fenbendazole in Calcium Alginate Sodium Alginate (40.0 g) was dissolved in hot water (2 kg) with vigorous stirring. Fenbendazole (100 g) was added and the resulting suspension homogenised using a high 15 shear Silverson mixer, before dilution with water (1 Kg).
Calcium chloride (45.0 g) was dissolved in water (3 Kg) and agitated in a large diameter bowl. The fenbendazole-alginate suspension was sprayed into the calcium chloride solution, setting the alginate, and generating a slurry of fenbendazole entrained in alginate gel. The slurry was filtered, oven dried, then graded through 'Endecott' precision sieves to 20 give the encapsulated Fenbendazole with a particle size predominately in the range 150500 tm which was analysed for free fenbendazole according to the standard test conditions.
Particle Size Free Fenbendazole Total Fenbendazole Content 150[tm 16.6% 52.9% 250[Lm 10.6% 66.2% 500tin 6.2% 76.9% Example 2: Encasulation of Fenbendazole in Gelatine - Acacia Gelatine (10 g) and acacia (10 g) were dissolved separately in water at 401C. Fenbendazole (20 g) was added to the gelatine solution and the resulting suspension homogenised using a high shear Silverson mixer. The acacia solution was added, the suspension re-homogenised and then diluted to a concentration of 1.5% (w/v) based on the individual colloids. The pH of the suspension was adjusted to 4.5 over I hour by the addition of 10% acetic acid in water, held for I hour at 40'C then cooled to I 5'C over 2 hours. The solution was diluted with isopropanol (200 ml), filtered then dried to give free flowing particles. These were graded through 'Endecott' precision sieves to give the encapsulated Fenbendazole with a particle size predominately in the range 150-500 tm, which was analysed for free fenbendazole according to the standard test conditions.
Particle Size Free Fenbendazole Total Fenbendazole Content 250gin 4.6% 43% Example 3: Encapsulation of Praziquantel in Calcium Alginate Sodium Alginate (8.4 g) was dissolved in hot water (700 g) with vigorous stirring. Praziquantel (5.2 g) was added and the resulting suspension homogenised using a high shear Silverson mixer. Calcium chloride (11.2 g) was dissolved in water (800 g) and agitated in a large diameter bowl. The praziquantel-alginate suspension was sprayed into the calcium chloride solution, setting the alginate, and generating a slurry of praziquantel entrained in alginate gel. The slurry was filtered and the resultant high moisture content solid analysed for free Praziquantel according to the standard test conditions.
12 Anal3jical Procedure for Determination of Free Fenbendazole and Praziguantel Methanol - DMSO (9:1) was demonstrated as a suitable solvent for the free active while having the potential to leave the encapsulating materials intact over a short time period (Based on data obtained from The Merck Index (I Ith Edition), Merck and Co, 1989). The sample was diluted with solvent in a 50 ml volumetric flask, shaken for 2 minutes to dissolve free active then sample. The sample was analysed by HPLC against an external standard (C18 column, eluant 70:30 MeOH: H20, flow rate 1.5ml.min, detection at 290 Dm) to give a To value for free active. The solution was samples over the course of 2 hours to give an indication of the degradation rate of the wall and the leach rate from the capsule.
In order to determine the total active content of the capsules, the capsules were ground with methanol - DMSO (9: 1) in order to mechanically disrupt the capsule walls, sonicated for 15 minutes to ensure full dissolution of the released active, then analysed by HPLC.
Time (mins) 150tm 250tm 500tum 0 16.6% 10.6% 6.2% 19.5% 12.4% 8.1% 22.5% 14.8% 10.3% 24.6% 16.5% 11.3% 25.1% 16.8% 11.7% Total Fenbendazole Content 52.9% 66.2% 76.9%
Claims (19)
1. A food product for the oral delivery of a pharmaceutical agent to a non-human animal comprising particles of said agent dispersed substantially uniformly within a palatable food matrix, wherein each of said particles is encapsulated within a substantially inert coating.
2. A food product according to claim 1, wherein said pharmaceutical agent is an anti parasitic agent, an agent with efficacy against stiffness or arthritis, a component of a vaccine, an anti-flatulence agent, or an agent effective against unpleasant breath odour.
3. A food product according to claim 2, wherein said anti-parasitic agent is an anti worming agent.
4. A food product according to any one of the preceding claims, wherein said encapsulated particles are between 1nni and lmm. in diameter.
5. A food product according to claim 4, wherein said encapsulated particles are between 20run and I 0ORm in diameter.
6. A food product according to any one of the preceding claims, which is formed as a tablet, lozenge, strip or chew.
7. A food product according to claim 6, wherein said product is molded.
8. A food product according to any one of claims 1-5, wherein said food matrix comprises liquid milk.
9. A food product according to any one of the preceding claims, wherein said palatable food matrix comprises a meat or fish derivative.
10. A food product according to any one of the preceding claims, wherein said inert coating comprises ethylcellulose, gelatine or gum arabica.
11. A food product according to any one of the preceding claims, wherein the amount of said pharmaceutical agent in the product corresponds to a recommended unit dose for a unit of animal bodyweight.
14
12. A food product according to claim 11, wherein said unit of animal bodyweight is a I Okg unit.
13. A food product according to any one of the preceding claims, wherein said product is divided into defined segments.
14. A package comprising one or more food products according to any one of the preceding claims.
15. A process for the production of a food product containing a pharmaceutical agent suitable for administration to a non-human animal, comprising the step of dispersing particles of said agent substantially uniformly within a palatable food matrix, wherein each of said particles is encapsulated within a substantially inert coating.
16. A food product according to any one of claims I -1 3), for use in therapy of a non-human animal.
17. Use of particles of a pharmaceutical agent encapsulated within a substantially inert coating in the manufacture of a medicament for the treatment or prevention of a disease in a non-human animal, wherein said particles are dispersed within a palatable food matrix.
18. Use according to claim 17, wherein said disease is a parasitic infection, arthritis or stiffness.
19. A method of treating a disease, or of preventing the incidence of a disease in a non human animal, comprising administering to said animal, a food product according to any one of claims 1- 11
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9927474A GB2356346A (en) | 1999-11-19 | 1999-11-19 | Food product for oral delivery of a pharmaceutical agent to a non-human animal comprising encapsulated particles of said agent distributed within the product |
AU14066/01A AU1406601A (en) | 1999-11-19 | 2000-11-17 | Food product comprising encapsulated drugs |
PCT/GB2000/004405 WO2001035925A1 (en) | 1999-11-19 | 2000-11-17 | Food product comprising encapsulated drugs |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9927474A GB2356346A (en) | 1999-11-19 | 1999-11-19 | Food product for oral delivery of a pharmaceutical agent to a non-human animal comprising encapsulated particles of said agent distributed within the product |
Publications (2)
Publication Number | Publication Date |
---|---|
GB9927474D0 GB9927474D0 (en) | 2000-01-19 |
GB2356346A true GB2356346A (en) | 2001-05-23 |
Family
ID=10864855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB9927474A Withdrawn GB2356346A (en) | 1999-11-19 | 1999-11-19 | Food product for oral delivery of a pharmaceutical agent to a non-human animal comprising encapsulated particles of said agent distributed within the product |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU1406601A (en) |
GB (1) | GB2356346A (en) |
WO (1) | WO2001035925A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO5400144A1 (en) * | 2002-03-11 | 2004-05-31 | Novartis Ag | ORGANIC COMPOUNDS |
EP1362583A1 (en) * | 2002-05-15 | 2003-11-19 | CUM Taste Masking AG | Process for masking the taste of substances by microencapsulation |
EP1759692A3 (en) * | 2003-03-10 | 2007-09-12 | Novartis AG | Taste-masked solid veterinary compositions |
EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
US7348027B2 (en) * | 2005-04-08 | 2008-03-25 | Bayer Healthcare Llc | Taste masked veterinary formulation |
EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
US8940344B2 (en) | 2007-06-08 | 2015-01-27 | Philip Morris Usa Inc. | Capsule clusters for oral consumption |
FR2940910A1 (en) * | 2009-01-09 | 2010-07-16 | Vetoquinol Sa | NEW S-ADENOSYL-METHIONINE COMPRESSOR |
US10398705B2 (en) | 2012-03-15 | 2019-09-03 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
FR3002735B1 (en) | 2013-03-04 | 2015-07-03 | Virbac | ORAL NUTRITIONAL COMPOSITION AND MEDICAMENT FOR VETERINARY USE |
FR3002736B1 (en) | 2013-03-04 | 2015-06-26 | Virbac | ORAL NUTRITIONAL COMPOSITION AND MEDICAMENT FOR VETERINARY USE |
WO2015007760A1 (en) | 2013-07-19 | 2015-01-22 | Boehringer Ingelheim Vetmedica Gmbh | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
CN110721164A (en) | 2013-12-04 | 2020-01-24 | 勃林格殷格翰动物保健有限公司 | Improved pharmaceutical composition of pimobendan |
US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
WO2018026810A1 (en) * | 2016-08-03 | 2018-02-08 | Vanderbilt University | Treatment methods using celastrol |
US20210007977A1 (en) * | 2018-02-19 | 2021-01-14 | Monell Chemical Senses Center | Compositions and methods of ameliorating pharmaceutical aversiveness with salts |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2147501A (en) * | 1983-10-03 | 1985-05-15 | Avner Rotman | Encapsulated medicament in sweet matrix |
GB2186485A (en) * | 1986-02-13 | 1987-08-19 | Ethical Generics Ltd | Slow release formulation |
US4804548A (en) * | 1984-10-05 | 1989-02-14 | Warner-Lambert Company | Novel sweetener delivery systems |
US4851232A (en) * | 1987-02-13 | 1989-07-25 | Alza Corporation | Drug delivery system with means for obtaining desirable in vivo release rate pattern |
US5780056A (en) * | 1996-05-10 | 1998-07-14 | Lion Corporation | Microcapsules of the multi-core structure containing natural carotenoid |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU744156B2 (en) * | 1996-10-28 | 2002-02-14 | General Mills Inc. | Embedding and encapsulation of controlled release particles |
-
1999
- 1999-11-19 GB GB9927474A patent/GB2356346A/en not_active Withdrawn
-
2000
- 2000-11-17 WO PCT/GB2000/004405 patent/WO2001035925A1/en active Application Filing
- 2000-11-17 AU AU14066/01A patent/AU1406601A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2147501A (en) * | 1983-10-03 | 1985-05-15 | Avner Rotman | Encapsulated medicament in sweet matrix |
US4804548A (en) * | 1984-10-05 | 1989-02-14 | Warner-Lambert Company | Novel sweetener delivery systems |
GB2186485A (en) * | 1986-02-13 | 1987-08-19 | Ethical Generics Ltd | Slow release formulation |
US4851232A (en) * | 1987-02-13 | 1989-07-25 | Alza Corporation | Drug delivery system with means for obtaining desirable in vivo release rate pattern |
US5780056A (en) * | 1996-05-10 | 1998-07-14 | Lion Corporation | Microcapsules of the multi-core structure containing natural carotenoid |
Also Published As
Publication number | Publication date |
---|---|
GB9927474D0 (en) | 2000-01-19 |
AU1406601A (en) | 2001-05-30 |
WO2001035925A1 (en) | 2001-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2356346A (en) | Food product for oral delivery of a pharmaceutical agent to a non-human animal comprising encapsulated particles of said agent distributed within the product | |
JP6544837B2 (en) | Enzyme delivery system and method of preparation and method of use | |
CA2632855C (en) | Process for manufacturing chewable dosage forms for drug delivery and products thereof | |
US4749575A (en) | Microencapsulated medicament in sweet matrix | |
EP2144599B1 (en) | Sustained release pellets comprising wax-like material | |
US4786508A (en) | Coated dosage forms | |
JP5162071B2 (en) | Method and apparatus for producing a liquid dosage formulation | |
CN1088362C (en) | Method of administering azithromycin | |
EP2331076B1 (en) | Chewable sustained release formulations | |
EP1490037B1 (en) | Taste masked veterinary solid compositions | |
MXPA05000976A (en) | Palatable controlled-release formulation for companion animals. | |
CN101277701A (en) | Pharmaceutical preparation containing meloxicam | |
JP2019513146A (en) | Compositions and methods for selective GI tract delivery | |
EP2923582B1 (en) | Pet food compositions including sustained-release lipoic acid | |
CA2350519C (en) | Chromone enteric release formulation | |
Adenot et al. | Palatability assessment of oral dosage forms for companion animals: A systematic review | |
EP1158977B1 (en) | Composition for administering a cyclooxygenase-2 inhibitor to animals | |
Kulkarni et al. | Recent trends on achieving taste masking of bitter drug | |
JP2004194514A (en) | Medicine palatable for pet | |
EP1926475A1 (en) | Oral vehicle for systemic pharmaceuticals | |
RU2778848C2 (en) | The composition of fenfluramine, compatible with a ketogenic diet | |
WO2023105397A1 (en) | Tablets comprising chondroitin sulphate, glucosamine hydrochloride, and vitamin c for the treatment of cartilage, tendon, bone damages | |
US20190000766A1 (en) | Abuse deterrent soft chewable drug formulations | |
JP2022013368A (en) | Veterinary pharmaceutical formulation | |
JP3031509U (en) | Oral drugs and processed foods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |